β-Adrenergic Receptor Polymorphisms and Response to Salmeterol
暂无分享,去创建一个
Vernon M. Chinchilli | Homer A. Boushey | Monica Kraft | Stanley J. Szefler | Christine A. Sorkness | Timothy J. Craig | Richard J. Martin | Robert F. Lemanske | E. Israel | H. Boushey | C. Sorkness | Richard J Martin | S. Peters | V. Chinchilli | S. Szefler | S. Lazarus | F. Leone | M. Kraft | E. Lehman | M. Wechsler | J. Fahy | R. Lemanske | T. Craig | A. Deykin | Elliot Israel | E. DiMango | John V. Fahy | Stephen C. Lazarus | Stephen P. Peters | Michael E. Wechsler | Erik Lehman | Aaron Deykin | Emily DiMango | Frank T. Leone | Wenlei Liu | Wenlei Liu
[1] R S Judson,et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] C Summers,et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.
[3] E. Israel,et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.
[4] E. Silverman,et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.
[5] P. Ind,et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.
[6] P. Ross,et al. High level multiplex genotyping by MALDI-TOF mass spectrometry , 1998, Nature Biotechnology.
[7] I. Hall,et al. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. , 2003, British journal of clinical pharmacology.
[8] W. Castle,et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. , 1993, BMJ.
[9] E. Israel,et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. , 2001, JAMA.
[10] R. Erickson,et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.
[11] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[12] E. R. Mcfadden,et al. Effect of long-term salmeterol treatment on exercise-induced asthma. , 1998, The New England journal of medicine.
[13] B. Kobilka,et al. Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox , 2003 .
[14] H. Bisgaard. Effect of long‐acting β2 agonists on exacerbation rates of asthma in children , 2003, Pediatric pulmonology.
[15] A. Markham,et al. AMPLIFICATION REFRACTORY MUTATION SYSTEM FOR PRENATAL DIAGNOSIS AND CARRIER ASSESSMENT IN CYSTIC FIBROSIS , 1989, The Lancet.
[16] R. Hudson,et al. Statistical properties of the number of recombination events in the history of a sample of DNA sequences. , 1985, Genetics.
[17] C. Print,et al. Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.
[18] E. Israel,et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. , 1996, The New England journal of medicine.
[19] T. Haahtela,et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.
[20] J. Drazen,et al. Asthma exacerbations during long term â agonist use : influence of â 2 adrenoceptor polymorphism , 2000 .
[21] R. Nicklas,et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. , 2003, Chest.
[22] E. Boerwinkle,et al. Influence of the β2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study , 2002, International Journal of Obesity.
[23] E. Silverman,et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. , 2005, American journal of respiratory and critical care medicine.
[24] M. Kennedy,et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. , 2005, American journal of respiratory and critical care medicine.
[25] M. Sears,et al. Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.
[26] N. Laird,et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. , 2003, The Journal of allergy and clinical immunology.
[27] J. Drazen,et al. β-Agonists and asthma: too much of a good thing? , 2003 .
[28] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[29] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[30] A. Woolcock,et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.
[31] D. Postma,et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.
[32] S. Gabriel,et al. The Structure of Haplotype Blocks in the Human Genome , 2002, Science.
[33] A. Wanner. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes. , 1995, American journal of respiratory and critical care medicine.
[34] Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. , 1994, JAMA.
[35] D. Schaid,et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.
[36] H. Nelson. β-Adrenergic Bronchodilators , 1995 .
[37] Vernon M. Chinchilli,et al. Long-Acting β2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial , 2001 .
[38] R. Dockhorn,et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. , 1994, The Journal of allergy and clinical immunology.
[39] J. Kemp,et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.